1. Home
  2. Vol 18, No 3 (2024)
  3. Andayani

The Correlation of Neutrophil-Lymphocyte Ratio (NLR) and the Response Evaluation Criteria in Solid Tumors (RECIST) in Non-small Cell Lung Cancer (NSCLC) Patient

Novita Andayani, Yunita Arliny

Abstract


Background: The biological marker Neutrophil-Lymphocyte Ratio (NLR) is still being studied for its effectiveness as a predictor of prognosis and treatment response to cancer. This study aims to assess the effectiveness of the NLR as a prognostic biomarker in Non-small Cell Lung Cancer (NSCLC) patients.

 

Methods: This observational study with a cross-sectional design intends to determine the effect of NLR on the response to the treatment of the patients as measured by Response Evaluation Criteria in Solid Tumors (RECIST). The samples collected were advanced-stage NSCLC patients who underwent chemotherapy from January 2021 to December 2022 to assess the prognosis and its relationship with NLR. The area Under the Curve Receiver Operating Characteristic (AUC ROC) curve was used to see the sensitivity, specificity, and cut-off point.

 

Results: Sixty-seven samples met the criteria of the samples’ study. The best NLR cut-off point was 4.335 with a sensitivity of 86.7% and a specificity of 55.5%. The AUC value was 0.701 with a significance of 0.019. NLR values above the cut-off point were more frequently found in patients with progressive disease (29 samples; 43.3%).

 

Conclusions: This study showed that there was a relationship between NLR and RECIST in NSCLC patients. NLR was quite effective as a prognostic biomarker of NSCLC patients who underwent chemotherapy.


Keywords


neutrophil-lymphocyte ratio, non-small cell lung cancer, RECIST, prognosis

Full Text: View | Download

DOI: 10.33371/ijoc.v18i3.1178

Article Metrics

Abstract View: 87,
PDF Download: 25
             

References


Minkov P, Gulubova M, Chilingirov P, Ananiev J. The Position of Neutrophils-To-Lymphocytes and Lymphocytes-To-Platelets Ratio as Predictive Markers of Progression and Prognosis in Patients with Non-Small Cell Lung Cancer. Open Access Maced J Med Sci. 2018 Aug 4;6(8):1382–6.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan 12;72(1):7–33.

Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunology, Immunotherapy. 2013 Mar 18;62(3):471–9.

Ksienski D, Wai ES, Alex D, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. Transl Lung Cancer Res. 2021 Jan;10(1):355–67.

Chaitanya Thandra K, Barsouk A, Saginala K, et al. Epidemiology of lung cancer. Współczesna Onkologia. 2021;25(1):45–52.

American Cancer Society. https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. About Lung Cancer.

American Lung Association. State of Lung Disease in Diverse Communities 2010 [Internet]. New York; 2010. Available from: http://www.LungUSA.org

Rahal Z, El Nemr S, Sinjab A, et al. Smoking and Lung Cancer: A Geo-Regional Perspective. Front Oncol. 2017 Sep 1;7.

Faot NE, Pradjoko I. Rasio Neutrofil-Limfosit Sebelum Kemoterapi dan Respons Obyektif Kemoterapi Pasien Kanker Paru dengan Kemoterapi Berbasis Platinum Correlation Between Neutrofil-Limphocyte Ratio Before Chemoteraphy and Objective Response Platinum based Chemoteraphy on Lung Cancer Patient. J Respir Indo. 2017;37(4):293–301.

Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017 Sep;111:176–81.

Koswara T, Iriawan J, Surya F. Karakteristik karsinoma paru bukan sel kecil dan hasil pemeriksaan EGFR di RSUP dr. Hasan Sadikin periode tahun 2018-2020. Medika Kartika Jurnal Kedokteran dan Kesehatan. 2022 Jun 30;(Volume 5 No 2):150–61.

Porcel JM, Esquerda A, Vives M, Bielsa S. Etiología del derrame pleural: análisis de más de 3.000 toracocentesis consecutivas. Arch Bronconeumol. 2014 May;50(5):161–5.

Popper HH. Progression and metastasis of lung cancer. Cancer and Metastasis Reviews. 2016 Mar 28;35(1):75–91.

Wibowo A, Ratu N, Kharima N, Jusuf A. Delayed Diagnosis in Lung Cancer. JK Unila. 2021 Dec;5(2):156–8.

Vinas F, Ben Hassen I, Jabot L, et al. Delays for diagnosis and treatment of lung cancers: a systematic review. Clin Respir J. 2016 May 3;10(3):267–71.

Malalasekera A, Nahm S, Blinman PL, et al. How long is too long? A scoping review of health system delays in lung cancer. European Respiratory Review. 2018 Sep 30;27(149):180045.

Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. Int J Mol Sci. 2022 Mar 26;23(7):3636.

Akinci Ozyurek B, Sahin Ozdemirel T, Buyukyaylaci Ozden S, et al. Prognostic Value of the Neutrophil to Lymphocyte Ratio (NLR) in Lung Cancer Cases. Asian Pac J Cancer Prev. 2017 May 1;18(5):1417–21.

Quail DF, Amulic B, Aziz M, et al. Neutrophil phenotypes and functions in cancer: A consensus statement. Journal of Experimental Medicine. 2022 Jun 6;219(6).

Fridlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. 2012 May 1;33(5):949–55.

Chraa D, Naim A, Olive D, Badou A. T lymphocyte subsets in cancer immunity: Friends or foes. J Leukoc Biol. 2019 Jan 31;105(2):243–55.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.